Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- SELF-MEDICATION NEWS IN BRIEF
January 5, 2009
- Teijin Expects Approval of TMX-67 in US
December 22, 2008
- 33 Multinational Clinical Trials Reported in First 6 Months of FY2008
December 22, 2008
- BioWa Extends POTELLIGENT Technology License Agreement with GSK
December 22, 2008
- Okayama Univ. to Test REIC Gene Medicine in US
December 22, 2008
- DSP to Centralize Chinese Business Activities in Suzhou
December 22, 2008
- ICH GL for Exploratory Clinical Studies to Be Completed in June 2009
December 22, 2008
- Market in Emerging Countries to Grow to about US$300 Bil. in 2017
December 22, 2008
- R&D NEWS IN BRIEF
December 22, 2008
- AZ, BMS to Jointly Commercialize Dapagliflozin in Japan
December 22, 2008
- 7 Organizations Call For Further Discussions on Online Sales of Drugs
December 22, 2008
- Sales of Cytotoxic Chemotherapeutics to Peak at US$16.5 Bil. in 2013
December 22, 2008
- Regulatory Reform Council to Not Include Online Sales of Drugs in Its Recommendation
December 22, 2008
- BUSINESS NEWS IN BRIEF
December 22, 2008
- Crestor Reduces CV Risk in Patients with High High-Sensitive CRP Levels: JUPITER Study
December 22, 2008
- New Fees Related to Generics Claimed by Only a Few Pharmacies
December 22, 2008
- Control of Postprandial Hyperglycemia Important to Prevent CV Events: Prof. Tajima
December 22, 2008
- Most Women Have Not Been Examined for Breast Cancer Despite Willingness
December 22, 2008
- High % of ED Patients with Underlying Conditions Satisfied with Levitra: Bayer Schering
December 22, 2008
- Nichi-Iko Merges 3 Subsidiaries
December 22, 2008
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…